我院抗肿瘤辅助用药分析及干预措施  

Analysis of Anti-tumor Adjuvant Drugs and Interventions in Our Hospital

作　　者：司宏[1] 徐艳艳[1] 倪美鑫[1] 

机构地区：[1]南通市肿瘤医院药剂科,江苏南通226361

出　　处：《中国药房》2015年第11期1565-1567,共3页China Pharmacy

摘　　要：目的:促进抗肿瘤辅助用药的安全、合理和经济使用。方法:回顾性分析我院2013年1-6月(干预前)和7-12月(干预后)抗肿瘤辅助用药应用情况及评价干预效果。结果:通过技术干预、行政干预、信息干预等措施,不合理使用抗肿瘤辅助用药得到有效改善,抗肿瘤辅助用药占药品总收入的比例,干预前为59.07%,干预后为47.17%,下降11.90%。结论:肿瘤治疗中辅助用药目前尚缺少客观和系统的评价依据,通过临床查找循证证据,客观评价用药合理性,逐步规范辅助用药行为,可以规避用药风险。OBJECTIVE：To promote the safety,rationality and economy use of anti-tumor adjuvant drugs. METHODS：The application of anti-tumor adjuvant drugs in our hospital in Jan.-Jun.（before intervention） and Jul.-Dec. 2013（after intervention）was retrospective analyzed and the effects of intervention was evaluated. RESULTS：According to the measures of technological intervention,administrative intervention and information intervention,etc,the irrational use of anti-tumor adjuvant drugs was improved. The proportion of anti-tumor adjuvant drugs in total income of drugs was decreased from 59.07%（before intervention）to47.17%（after intervention）,decreasing 11.90%. CONCLUSIONS：Adjuvant drugs are still lack of objective and system evaluation basis. The medication risks can be avoided by finding evidence-based clinical evidence,objectively evaluating the rationality of medication and can gradually standardizing the behavior of adjuvant.

关 键 词：抗肿瘤辅助用药 分析 干预措施 

分 类 号：R969.3[医药卫生—药理学] R952[医药卫生—药学]